Related Experiment Video
Updated: Nov 1, 2025
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
Nonviral siRNA delivery systems for pancreatic cancer therapy
Shahin Aghamiri1,2, Pourya Raee3, Sam Talaei4
1Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)-based therapeutics. Recent advances in drug delivery systems hold great promise for improving siRNA-based therapeutics and developing a new class of drugs, known as nano-siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano-bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in the design and development of various nonviral delivery vehicles for pancreatic cancer therapy. More importantly, codelivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed.
Insights
Conventional pancreatic cancer treatments face challenges. This review explores nano-siRNA drug delivery systems and combination therapies for improved pancreatic ductal adenocarcinoma (PDAC) treatment, addressing key challenges for clinical use.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits significant resistance to conventional chemotherapy and radiation.
- Existing treatments for PDAC are limited by nonspecific toxicity and drug resistance.
- Small interfering RNA (siRNA)-based therapeutics offer a promising alternative for cancer treatment.
Purpose of the Study:
- To review recent advancements in nonviral delivery vehicles for pancreatic cancer therapy.
- To discuss the potential of nano-siRNA drugs for improved therapeutic efficacy.
- To explore the combination of conventional anticancer drugs with siRNA for pancreatic cancer treatment.
Main Methods:
- Review of current literature on siRNA delivery systems for pancreatic cancer.
- Analysis of nonviral vectors for nano-siRNA drug development.
- Discussion of challenges and opportunities in nano-siRNA clinical translation.
Main Results:
- Development of diverse nonviral delivery vehicles for pancreatic cancer therapy.
- Emerging nano-siRNA drugs show promise for overcoming treatment resistance.
- Codelivery strategies combining conventional drugs with siRNA represent a revolutionary approach.
Conclusions:
- Nano-siRNA drug delivery systems offer significant potential for pancreatic cancer treatment.
- Addressing toxicity, immunostimulation, and nano-bio interactions is crucial for clinical translation.
- Combinational therapy with nano-siRNA and conventional drugs presents a promising future for PDAC management.
More Related Videos
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi